A Pictorial Review of PI-RADS v2.0 and PI-RADS v2.1: What Changed?

Abstract

Prostate cancer (PCa) is the most common cancer among Canadian men (excluding nonmelanoma skin cancers) and is the third leading cause of death from cancer in men in Canada. It is estimated that, in 2020, 23,300 men will be diagnosed with PCa, representing 20% of all new cancer cases in men.1 The recommended technique being used for the detection and risk stratification of PCa is multiparametric MRI (mpMRI), which includes high-resolution T2-weighted (T2W) images to depict prostate anatomy and two functional MRI techniques, including diffusion-weighted imaging (DWI) to display cell density and dynamic contrast-enhanced MRI (DCE) that shows vascularity.2